101 related articles for article (PubMed ID: 467888)
1. Lymphocyte responsiveness to phytohemagglutinin and its modification by serum inhibitor in breast cancer patients.
Toge T; Nagusa Y; Nakano A; Ikeda H; Hattori T
Gan; 1979 Apr; 70(2):245-8. PubMed ID: 467888
[TBL] [Abstract][Full Text] [Related]
2. Variability of lymphocyte response to PHA in patients with operable breast carcinoma: effect of cell concentration, PHA dose, serum and period of cultivation.
Harrison RA; Lee H; Farrant J
Clin Oncol; 1981 Sep; 7(3):205-12. PubMed ID: 7343166
[No Abstract] [Full Text] [Related]
3. Correlation between lymphocyte responsiveness to mitogens and results of chemo-immunotherapy in patients with advanced cancer.
Toge T; Yamada Y; Ikeda H; Niimoto M; Hattori T
Gan; 1979 Oct; 70(5):699-703. PubMed ID: 520761
[TBL] [Abstract][Full Text] [Related]
4. [Lymphocyte subsets and response of breast cancer and benign mammary disease to PHA].
Nakao S; Hayashida K; Hasegawa H; Ishii T; Eida K; Noguchi K
Gan No Rinsho; 1987 Oct; 33(12):1453-8. PubMed ID: 3500331
[TBL] [Abstract][Full Text] [Related]
5. [Intact cellular immune response in patients with locally metastasizing breast carcinoma at the time of diagnosis].
Ludwig C; Hartmann D; Landmann R; Wesp M; Rosenfelder G; Stucki D; Buser M; Obrecht JP
Schweiz Med Wochenschr; 1983 Dec; 113(50):1908-11. PubMed ID: 6229873
[TBL] [Abstract][Full Text] [Related]
6. Enhanced viral inhibition of lymphocyte mitogenesis in patients with advanced breast cancer.
Margolese RG; Wainberg MA
Clin Exp Immunol; 1985 Oct; 62(1):85-94. PubMed ID: 2998661
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of lymphocyte immunity in breast cancer patients.
Head JF; Elliott RL; McCoy JL
Breast Cancer Res Treat; 1993; 26(1):77-88. PubMed ID: 8400326
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte reactivity to mitogens and tumor sex steroid receptors in breast cancer patients.
Kastelan M; Rudolf M; Hrsak M; Stojkovic R; Gamulin S
Biomed Pharmacother; 1985; 39(8):442-4. PubMed ID: 3834952
[TBL] [Abstract][Full Text] [Related]
9. Induction of impaired activation of lymphocytes by suppressive factor in Crohn's disease patients.
Watanabe M; Tsuru S; Aiso S; Hibi T; Yoshida T; Asakura H; Zinnaka Y; Tsuchiya M
J Clin Lab Immunol; 1984 May; 14(1):29-34. PubMed ID: 6748044
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancer.
Toge T; Ikeda H; Senoo N; Niimoto M; Hattori T
Jpn J Surg; 1976 Dec; 6(4):157-63. PubMed ID: 1018347
[TBL] [Abstract][Full Text] [Related]
11. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder carcinoma.
Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Invest Urol; 1979 Mar; 16(5):342-5. PubMed ID: 429128
[TBL] [Abstract][Full Text] [Related]
12. [Cellular immunity in breast cancer patients].
Spielmann M; Kitschke HJ; Tietje K
Onkologie; 1982 Aug; 5 Suppl():42-5. PubMed ID: 6752790
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of lymphocyte responses to phytohemagglutinin in melanoma patients. (lack o prognostic value of correlation with minimal tumor burden).
Kovarík J; Ninger E; Zemanová D; Lauerová L
Neoplasma; 1980; 27(5):575-82. PubMed ID: 7231613
[TBL] [Abstract][Full Text] [Related]
14. Deficient concanavalin-A-induced suppressor cell activity in women with untreated breast cancer.
Gupta S; Cunningham-Rundles S
J Clin Lab Immunol; 1982 Dec; 9(3):159-61. PubMed ID: 6220154
[TBL] [Abstract][Full Text] [Related]
15. Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patients.
Mantovani G; Serri FG; Macciò A; Castelli P; Benedetti P; Scambia G; Santus S; Paderi R; Murtas MG; Ferreli A
Cancer Detect Prev; 1989; 13(5-6):323-32. PubMed ID: 2743354
[TBL] [Abstract][Full Text] [Related]
16. Active lymphocyte traffic induced in the periphery by cytokines and phytohemagglutinin: three different mechanisms?
Binns RM; Licence ST; Wooding FB; Duffus WP
Eur J Immunol; 1992 Sep; 22(9):2195-203. PubMed ID: 1516613
[TBL] [Abstract][Full Text] [Related]
17. PHA responsiveness and adherent cell-lymphocyte interactions in patients with advanced malignant tumors of the ovary prior to treatment and during chemotherapy.
Markowska J; Jaroszewski J; Jankowiak S; Wiktorowicz K; Jaskulska T
Neoplasma; 1986; 33(3):361-9. PubMed ID: 3736722
[TBL] [Abstract][Full Text] [Related]
18. [Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer].
Hisamatsu K; Toge T; Yanagawa E; Hamada Y; Seto Y; Yamada H; Toi M; Hattori T
Gan To Kagaku Ryoho; 1986 Aug; 13(8):2555-61. PubMed ID: 2943228
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent responsiveness of T lymphocytes to allogeneic and PHA stimulation.
Onody C; Bátory G; Patrányi GG
Thymus; 1980 Jan; 1(4-5):205-13. PubMed ID: 6969472
[TBL] [Abstract][Full Text] [Related]
20. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors.
Elliott LH; Brooks WH; Roszman TL
J Immunol; 1984 Mar; 132(3):1208-15. PubMed ID: 6319491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
